DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20202914

Case report of bullous pemphigoid in a 65 year old woman

Bolaji Otikeodibi, Ekechi S. Amadi, Dasetima D. Altraide, Belema O. Abbey, Okezie Ugwa

Abstract


The unique thing about this case is that it is the first reported case of bullous pemphigoid in the elderly that has been clinically diagnosed with histologic findings highly suggestive of this blistering disorder although an immunofluorescence could not be done due to unavailability in the centre. Patient was managed successfully and discharged home with improvement on subsequent hospital visits. This case report shows how diagnosis of an immunobullous disease was made and managed in a resource poor setting. A descriptive summary of 65-year old black Nigerian woman with bullous pemphigoid covering history, physical examination and management. The main diagnosis was bullous pemphigoid in a recently diagnosed type 2 diabetic. Patient was placed on corticosteroids as well as immunosuppressive agents and diabetes was managed with subcutaneous insulin and oral hypoglycemics with appropriate wound care. Patient showed remarkable improvement after management and was discharged home with subsequent follow up in the clinics. Bullous Pemphigoid (BP) can be diagnosed clinically with a high index of suspicion with the aid of skin biopsy and histology, and can be managed successfully even in a resource poor centre where immunofluorescence facilities are lacking.


Keywords


Autoimmune, Bullous pemphigoid, Drug-induced, Elderly

Full Text:

PDF

References


Katavic SS, Tanackovic SF, Badurina B. Illness Perception and Information Behaviour of Patients with Rare Chronic Diseases. Infor Res: Int Electr J. 2016 Mar;21(1):n1.

MacDonald A. The Challenge of Diagnosing Rare Diseases. Technol Net.2018;2018.

Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Frontiers Med. 2018 Aug 20;5:220.

Chung T, Korkji W, Sottani K, Clayman J, Cook J. Increased frequency of diabetes mellitus in patients with bullous pemphigoid: A case control study. JAAD Case reports.1984;11(6):1099-102.

Geller S, Kremer N, Zeeli T, Spreacher F. Bullous pemphigoid and diabetes mellitus, Are we missing a bigger picture?’ JAAD Case Reports. 2018;79(2):e27.

Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V. A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors. JAMA Dermatol. 2013;149(2):143-5.

Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018 Jun 1;78(6):1090-6.

Agarwala MK, Mukhopadhyay S, Sekhar MR, Peter CD. Bullous fixed drug eruption probably induced by paracetamol. Indian J Dermatol. 2016 Jan;61(1):121.

Jayshree A, Prashanth S, Chandra J, Veena K, Laximikanth C. Drug -Induced bullous pemphigoid: Expect the Unexpected. World J Dent. 2016;2(2):151-3.

Ogun G, Okoro E. The spectrum of non- neoplastic skin lesions in Ibadan, Nigeria: a histopathologic study. The Pan African Medical J. 2016;23:221.

Zienna, B., and Eiston, D., Pemphigus Vulgaris, Available at https://emedicine.medscape.com/article/1064187-overview#a1, Accessed 1st November 2019.

Reinhart J, Eiston D. Epi dermolysis Bullous Acquisita. 2019;2019.

Pinney SS, Eiston DM. Bullous Systemic Lupus Erythromatosus. Medscape. 2018;2018.

Stanley R. Bullous Pemphigoid in Wolff K. Fitzpatrick ‘s Dermatology in General Medicine, Oxford, McGraw- Hill; 2008:475-513.

Pathway Medicine, Bullous Pemphigoid, Available at http://www.pathwaymedicine.org/bullous-pemphigoid. Accessed 1st November 2019

Chan L, Eiston DM. Bullous pemphigoid, Medscape.2019;2019.

Haburchak DR, Chandrasekar PH. Hookworm disease, Medscape. 2018.

Mayo Clinic. Prednisolone and other corticosteroids. Available at https://www.mayoclinic.org/steroids/art-20045692, Accessed 2nd November 2019

Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Investigative Dermatol. 2011 Mar 1;131(3):637-43.

Greaves MW, Burton JL, Marks J, Dawber RP. Azathioprine in treatment of bullous pemphigoid. Br Med J. 1971 Jan 16;1(5741):144-5.

Dove Thr Bull. TPMT testing before azathioprine therapy?2009;47(1):9-12.

Torkami A, Roth K. Azathioprine metabolism and TPMT. Medscape. 2015;2015.